AGIOS PHARMACEUTICALS, INC. (AGIO) Stock Price, Financials & Summary

Price chart

Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15

Key dataSep 15, 2026

Open$33.23

From 52W high−27.87%

Volume1.07M

Market cap$1.96B

P/E (TTM)—

P/S (TTM)19.9x

Div yield—

Key dataSep 15, 2026

Open

$33.23

From 52W high

−27.87%

Volume

1.07M

Market cap

$1.96B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−3.3x

P/E (TTM)

—

RSI (14)

46.3

MomentumView details →

1D Return

−1.23%

YTD Return

+22.15%

SummaryUpdated Jun 1, 2026

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is a biopharmaceutical company founded in 2007 and headquartered in Cambridge, Massachusetts. The company went public in July 2013 and specializes in discovering and developing medicines targeting cellular metabolism and adjacent areas of biology. Agios has successfully commercialized its first product, PYRUKYND (mitapivat), for treating rare blood disorders, and maintains a robust pipeline of investigational therapies for various hemolytic anemias and other metabolic conditions.

Ask drillr about AGIOS PHARMACEUTICALS, INC. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−3.3x

EV/Sales

14.0x

P/S (TTM)

19.9x

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

87.92%

Net Margin

−418.24%

EBITDA Margin

−423.84%

ROE (TTM)

−40.09%

ROA (TTM)

−37.11%

Asset Turnover

0.09x

GrowthView details →

Revenue YoY

+140.58%

EPS YoY

—

FCF YoY

+10.70%

Revenue CAGR 3Y

+55.97%

EPS CAGR 3Y

—

EBITDA YoY

+1.68%

MomentumView details →

1D Return

−1.23%

YTD Return

+22.15%

1Y Return

−9.45%

RSI (14)

46.3

vs 50D SMA

−5.49%

vs 200D SMA

+8.48%

Capital & dividendView details →

Debt/Equity

0.03x

Current Ratio

10.22x

Quick Ratio

9.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.69

EPS Surprise

−2.42%

Beats (12Q)

6/12

Next Q EPS Est

−$1.21

Avg Surprise (4Q)

4.39%

Rev Surprise

70.87%

Financials snapshotView financials →

Revenue (TTM)

98.34M

Net Income (TTM)

−411.29M

Op. CF (TTM)

−360.60M

Next earningsOct 29, 2026 →

Latest newsMore news →

Assenagon Asset Management S.A. increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, acquiring 36,802 additional shares, according to a Form 13F filing.34d ago

Agios Pharmaceuticals advanced AG-236 into Phase 2/3 development for polycythemia vera.48d ago

Similar companies

AIM Vaccine Co., Ltd.06660.HK ADMA Biologics, Inc.ADMA Shanghai Bao Pharmaceuticals Co., Ltd.02659.HK Mesoblast LimitedMESO *ST海利603718.SH GH Research PLCGHRS Find similar companies →

Latest newsMore news →

Assenagon Asset Management S.A. increased its stake in Agios Pharmaceuticals, Inc. by 54.8% during the second quarter, acquiring 36,802 additional shares, according to a Form 13F filing.34d ago Agios Pharmaceuticals advanced AG-236 into Phase 2/3 development for polycythemia vera.48d ago Agios Pharmaceuticals licensed cevidoplenib for immune thrombocytopenia, diversifying its late-stage pipeline.48d ago